Published in Int J Cancer on July 15, 2001
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med (2002) 2.07
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol (2006) 1.86
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med (2007) 1.30
Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med (2004) 1.08
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep (2012) 1.05
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother (2011) 1.04
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Front Immunol (2014) 1.04
Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer (2007) 1.03
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother (2012) 1.02
Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol (2013) 1.02
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 1.00
Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 0.99
Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer (2003) 0.94
Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol Immunother (2012) 0.94
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines (2007) 0.91
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Int Rev Immunol (2011) 0.87
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology (2015) 0.87
Immunogenicity of targeted lentivectors. Oncotarget (2014) 0.86
Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. Transfusion (2009) 0.86
Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging (2005) 0.86
The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol (2010) 0.84
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther (2003) 0.82
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother (2016) 0.81
A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice. Front Microbiol (2013) 0.81
DNA is an efficient booster of dendritic cell-based vaccine. Hum Vaccin Immunother (2015) 0.81
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother (2013) 0.80
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med (2009) 0.80
Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. J Cancer Res Clin Oncol (2006) 0.79
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines (Basel) (2016) 0.77
Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. Exp Hematol (2009) 0.77
Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists. Cancer Immunol Immunother (2015) 0.76
A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells. PLoS One (2011) 0.76
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Hum Vaccin Immunother (2016) 0.76
Role of heterogeneous cell population on modulation of dendritic cell phenotype and activation of CD8 T cells for use in cell-based immunotherapies. Cell Immunol (2016) 0.75
Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself. Clin Immunol (2009) 0.75
Targeting the dendritic cell: the key to immunotherapy in cancer? Clin Exp Immunol (2005) 0.75
Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. Yonsei Med J (2011) 0.75
Chemokines as novel and versatile reagents for flow cytometry and cell sorting. J Immunol (2014) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
A physical map of the human genome. Nature (2001) 12.39
Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med (1985) 11.14
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol (2001) 10.35
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med (2001) 7.86
Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol (1998) 5.64
Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med (1987) 5.64
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med (1996) 5.29
Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med (1992) 5.03
Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods (1996) 4.87
Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 4.79
A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome. Nat Genet (2000) 4.78
Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 4.65
Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med (2000) 4.43
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell (1994) 4.04
Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat Immunol (2001) 3.89
Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation (2003) 3.86
Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods (1996) 3.80
Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol (1998) 3.75
Immunologic properties of purified epidermal Langerhans cells. Distinct requirements for stimulation of unprimed and sensitized T lymphocytes. J Exp Med (1986) 3.74
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 3.33
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol (1996) 3.24
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods (1999) 3.09
Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation (1998) 2.90
Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol (1999) 2.84
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci (2001) 2.75
The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. Ophthalmology (1996) 2.64
Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol (1989) 2.63
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood (1999) 2.47
Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA (2000) 2.29
Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation (2001) 2.28
Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol (1981) 2.28
Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol (2000) 2.24
Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol (2000) 2.24
Disappearance of certain acidic organelles (endosomes and Langerhans cell granules) accompanies loss of antigen processing capacity upon culture of epidermal Langerhans cells. J Exp Med (1990) 2.21
Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol (2001) 2.20
Expression of Thy-1 antigen by murine epidermal cells. J Invest Dermatol (1983) 2.20
Dendritic cells as vectors for therapy. Cell (2001) 2.18
Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest (1993) 2.16
Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse. J Cell Sci (1993) 2.15
Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol (1995) 2.11
Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol (1993) 2.10
Class II major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture. Proc Natl Acad Sci U S A (1991) 2.06
Orthopaedic workforce in the next millennium. J Bone Joint Surg Am (1998) 2.04
A radiation hybrid map of mouse genes. Nat Genet (2001) 2.03
The effect of aortic valve replacement on survival. Circulation (1982) 2.03
Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther (2000) 2.01
The Thy-1-bearing cell of murine epidermis. A distinctive leukocyte perhaps related to natural killer cells. J Exp Med (1985) 1.93
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer (1997) 1.86
Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles. J Vasc Surg (2002) 1.82
A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol (1997) 1.78
Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol (1998) 1.77
The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Springer Semin Immunopathol (1992) 1.68
Antibody cross-linking as a factor in immunity to cholera in infant mice. J Infect Dis (1975) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
A prospective study of Type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med (2004) 1.58
Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease. J Am Coll Cardiol (1999) 1.58
A comparison of murine epidermal Langerhans cells with spleen dendritic cells. J Invest Dermatol (1985) 1.57
Four-year follow-up study in patients with angina pectoris and normal coronary arteriograms ("syndrome X") Circulation (1989) 1.57
Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy (2000) 1.55
Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res (2010) 1.55
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy (2004) 1.55
Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol (2005) 1.54
Sensitivity, specificity, and predictive values of screening tests for eye conditions in a clinic-based population. Ophthalmology (1996) 1.52
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol (2011) 1.51
[Granuloma anulare disseminatum as a rare side effect of allopurinol]. Hautarzt (1995) 1.51
Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation (1997) 1.48
Annular peripheral choroidal detachment simulating aqueous misdirection after glaucoma surgery. Ophthalmology (1997) 1.46
Induction of hapten-specific tolerance by interleukin 10 in vivo. J Exp Med (1994) 1.46
Antibacterial mechanisms in the intestine. Elimination of V. cholerae from the intestines of infant mice and the role of antibody. Aust J Exp Biol Med Sci (1975) 1.46
Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells. J Immunol (1997) 1.46
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res (1999) 1.45
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res (2001) 1.43
Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med (2000) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39